Prelude reports Q2 2026 results, plans Phase 1 start for KAT6A degrader PRT13722
Prelude says it expects to initiate a Phase 1 study of PRT13722 in HR+ breast cancer in the fourth quarter, pending IND clearance, while enrollment continues for PRT12396 in PV and MF.
Prelude Therapeutics reported second quarter 2026 financial results on August 11, 2026 and provided a pipeline update. Pending clearance of the IND application, the company expects to initiate the Phase 1 study of PRT13722 in HR+ breast cancer in the fourth quarter of 2026.1 PRT13722 is described as a first-in-class, highly potent, highly selective and orally bioavailable KAT6A selective degrader.1 Prelude also presented preclinical data supporting this hypothesis at the AACR Annual Meeting 2026.1
For its other lead program, PRT12396, Prelude's lead, mutant-selective JAK2V617F inhibitor, received IND clearance from the FDA, as previously announced in February 2026, and is currently enrolling patients into a Phase 1 study in patients with PV and MF.1 That program is subject to an exclusive option agreement with Incyte announced in November 2025.1
On its third program, Prelude said it is advancing mCALR-targeted degrader antibody conjugates using the company's proprietary degrader payloads as a differentiated approach for patients with CALR mutations,1 and that this discovery program is wholly owned and controlled by Prelude.1
In April 2026, the company announced the appointment of Charles Morris, M.D. as Chief Medical Officer.1
On finances, Prelude reported cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026 were $155.2 million,1 and said this is expected to fund operations into the second quarter of 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.